Downstream Processing Featured Articles

  1. Waters And Dow Announce Major Breakthrough In Advanced Polymer Analysis At Pittcon 3/18/2013

    Waters Corporation recently unveiled several important new technologies at the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy, commonly known as Pittcon, the annual premier conference and exposition on laboratory science.

  2. RainDance Technologies And CLC Bio Collaborate To Develop Specialized Software Solutions For Targeted Resequencing 9/18/2009
    RainDance Technologies and CLC bio recently announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next-generation DNA sequencing platforms.
  3. Single-Use Standardization: Is It Holding Back The Biopharma Industry? 6/1/2015

    The data from BioPlan Associates’ 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production speaks to the industry’s ongoing desires for standardization in single-use devices. As usage of these disposable devices increases, the gap between the importance of standardization and end-users’ satisfaction with their supplier’s standardization efforts has steadily been worsening. 

  4. Combo Of Avastin, Second Drug Shows Promise Fighting Brain Cancer, Mayo Clinic Finds 2/14/2013

    The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood.

  5. Lonza And OncoMed Pharmaceuticals Sign A Process Development And Manufacturing Collaboration And Multi-Product GS License Agreement For Anti-Cancer Therapeutics 10/23/2012

    Lonza, a global leader in biological manufacturing and OncoMed Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to improving cancer treatment, announced recently an agreement for the development and manufacture of OncoMed’s pipeline of anti-cancer stem cell therapeutics.

  6. Thermo Fisher Scientific Forms Technology Alliance Partnership With The University Of Birmingham, UK 3/28/2013

    Thermo Fisher Scientific Inc., the world leader in serving science, has entered into a Technology Alliance Partner agreement with scientists at the University of Birmingham, UK, establishing a collaboration to accelerate research in high-resolution accurate mass (HRAM) and triple quadrupole liquid chromatography-mass spectrometry (LC-MS) for life science applications.

  7. BARDA Continues Novavax' Influenza Vaccine Programs Following In-Process Review 1/24/2013

    Novavax, Inc. (Nasdaq:NVAX) today announced that the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) has completed an In-Process Review (IPR) of Novavax' contract covering the company's recombinant virus-like particle (VLP) vaccine candidates for pandemic and seasonal influenza.

  8. Ablynx's Anti-IL-6R Nanobody, ALX-0061, Shows Excellent 24 Week Safety And Efficacy Results In A Phase II Clinical Trial In Rheumatoid Arthritis 2/13/2013

    Ablynx (EURONEXT BRUSSELS: ABLX) today announced efficacy and safety data for its anti-IL-6R Nanobody, ALX-0061, at the 24 week final analysis of the Phase II part of a combined Phase I/II study in patients with moderately to severely active rheumatoid arthritis (RA) on a stable background of methotrexate.

  9. Company Recognized For Outstanding Contributions To The Pharmaceutical Sciences 5/30/2012

     Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has awarded its 2012 Excellence in Ligand Binding Assays Award to the Bioanalytical Development group from Morphotek for their abstract, “Development and Validation of a Pharmacokinetic Assay on the Gyrolab Platform for Use in Phase II/III Clinical Studies.” The award was presented at the AAPS 2012 National Biotechnology Conference held May 21-23 in San Diego.
     

  10. The Benefits Of Genderless Sterile Connectors For Single-Use Applications

    Genderless connections are those in which the connector halves are identical in design, thus eliminating the need for different male and female halves to make the connection.